These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15867606)

  • 21. Drug-nutrient interactions and HIV.
    Maurice J
    Posit Aware; 2002; 13(4):38-9. PubMed ID: 12171042
    [No Abstract]   [Full Text] [Related]  

  • 22. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
    Jetter A; Fätkenheuer G; Frank D; Klaassen T; Seeringer A; Doroshyenko O; Kirchheiner J; Hein W; Schömig E; Fuhr U; Wyen C
    Antivir Ther; 2010; 15(7):975-83. PubMed ID: 21041912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of the pharmacogenetics of HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nácher I; Soriano V
    Pharmacogenomics J; 2006; 6(4):234-45. PubMed ID: 16462814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation, absorption and delivery of xenobiotics: the synergic role of CYP450 and P-gp activities.
    Colabufo NA
    Curr Drug Metab; 2011 Oct; 12(8):701. PubMed ID: 22150749
    [No Abstract]   [Full Text] [Related]  

  • 25. Understanding drug-drug interactions in the management of HIV disease.
    Edmunds-Obguokiri T
    HIV Clin; 2002; 14(2):1-4. PubMed ID: 12055962
    [No Abstract]   [Full Text] [Related]  

  • 26. Intestinal function and morphology after ex vivo irradiated small bowel transplantation.
    Ishikawa T; Iwanami K; Okuda T; Zhu Y; Fukuda A; Zhang S; Ou J; Nalesnik MA; Venkataramanan R; Murase N
    Transplant Proc; 2002 May; 34(3):988-9. PubMed ID: 12034274
    [No Abstract]   [Full Text] [Related]  

  • 27. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
    Patel J; Mitra AK
    Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
    Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
    Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-related drug metabolism and cytochrome P450 enzymes.
    Andrade A; Flexner C
    AIDS Clin Care; 2000 Nov; 12(11):91-5. PubMed ID: 12211165
    [No Abstract]   [Full Text] [Related]  

  • 30. Grapefruit juice activates P-glycoprotein-mediated drug transport.
    Soldner A; Christians U; Susanto M; Wacher VJ; Silverman JA; Benet LZ
    Pharm Res; 1999 Apr; 16(4):478-85. PubMed ID: 10227700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules.
    Hoggard PG; Back DJ
    Curr Opin Infect Dis; 2002 Feb; 15(1):3-8. PubMed ID: 11964899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age.
    Fakhoury M; Litalien C; Medard Y; Cavé H; Ezzahir N; Peuchmaur M; Jacqz-Aigrain E
    Drug Metab Dispos; 2005 Nov; 33(11):1603-7. PubMed ID: 16049125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mdr1 limits CYP3A metabolism in vivo.
    Lan LB; Dalton JT; Schuetz EG
    Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
    Wilby KJ; Greanya ED; Ford JA; Yoshida EM; Partovi N
    Ann Hepatol; 2012; 11(2):179-85. PubMed ID: 22345334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.
    Salphati L; Benet LZ
    Biochem Pharmacol; 1998 Feb; 55(4):387-95. PubMed ID: 9514072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug interactions in the management of HIV infection.
    Robertson SM; Penzak SR; Pau AK
    Expert Opin Pharmacother; 2005 Feb; 6(2):233-53. PubMed ID: 15757420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
    Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
    Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug interactions: new mechanisms and clinical relevance].
    Paneitz A; Meissner K; Kroemer HK
    Internist (Berl); 2000 Apr; 41(4):338-43. PubMed ID: 10798181
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacodynamics and clinical use of anti-HIV drugs.
    Preston SL; Piliero PJ; Drusano GL
    Infect Dis Clin North Am; 2003 Sep; 17(3):651-74. PubMed ID: 14711082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug interactions and anti-HIV therapy.
    Highleyman L
    BETA; 2005; 17(4):20-9. PubMed ID: 16124119
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.